Group 1: Company Performance - CVS Health closed at $67.91, with a 0.5% increase, lagging behind the S&P 500's 1.08% gain on the same day [1] - Over the past month, CVS shares gained 3.05%, outperforming the Medical sector's 0.21% gain and the S&P 500's 8.26% loss [1] Group 2: Earnings Projections - The upcoming earnings per share (EPS) for CVS Health is projected at $1.62, indicating a 23.66% increase year-over-year [2] - Revenue for the same quarter is estimated at $92.82 billion, reflecting a 4.95% rise from the previous year [2] Group 3: Fiscal Year Estimates - For the entire fiscal year, earnings are projected at $5.88 per share and revenue at $387.86 billion, representing increases of 8.49% and 4.04% respectively from the prior year [3] - Recent analyst estimate revisions suggest a favorable outlook on CVS Health's business health and profitability [3] Group 4: Valuation Metrics - CVS Health has a Forward P/E ratio of 11.48, which is lower than the industry's average Forward P/E of 16.13 [6] - The company has a PEG ratio of 1.02, compared to the Medical Services industry's average PEG ratio of 1.42 [6] Group 5: Industry Ranking - The Medical Services industry, which includes CVS Health, holds a Zacks Industry Rank of 71, placing it in the top 29% of over 250 industries [7] - Strong individual industry groups, as measured by the Zacks Industry Rank, tend to outperform weaker groups by a factor of 2 to 1 [7]

Group 1 - Aurora Cannabis Inc. is currently ranked 2 (Buy) in the Zacks Rank system, indicating a strong potential for outperforming the market in the next one to three months [3] - The Zacks Consensus Estimate for Aurora Cannabis Inc.'s full-year earnings has increased by 2400% over the past 90 days, reflecting a significant improvement in analyst sentiment [3] - Year-to-date, Aurora Cannabis Inc. has returned approximately 3.8%, outperforming the average return of 3.4% for the Medical sector [4] Group 2 - Aurora Cannabis Inc. belongs to the Medical - Products industry, which consists of 83 individual stocks and is currently ranked 141 in the Zacks Industry Rank [5] - The average return for stocks in the Medical - Products industry this year is 6.1%, indicating that Aurora Cannabis Inc. is slightly underperforming its industry [5] - Concentra Group, another Medical stock, has outperformed the sector with a year-to-date return of 5.1% and also holds a Zacks Rank of 2 (Buy) [4][5]

Core Insights - The integration of hospital data in Beijing has significantly improved patient convenience, allowing for seamless access to medical records without the need for physical documents [1][2] - The Beijing Health Commission reports that 60 clinical test results are now recognized across 914 medical institutions in the Beijing-Tianjin-Hebei region, enhancing service standardization [1][2] - The implementation of "cloud services" by various medical institutions allows patients to access their medical imaging and test data via mobile apps, streamlining the process for follow-up and referrals [1][2] Summary by Categories - **Data Interconnectivity**: The ability for hospitals to access CT and test results from other institutions within three months enhances patient care and reduces the need for physical documentation [1][2] - **Clinical Test Recognition**: 60 clinical test results are mutually recognized across 914 medical institutions, which includes secondary and tertiary hospitals, independent labs, and private medical facilities [1][2] - **Cloud Services Adoption**: Many medical institutions are offering cloud services, enabling patients to retrieve their medical history and imaging data through mobile technology, facilitating easier follow-ups and referrals [1][2]

Core Viewpoint - ModivCare reported quarterly earnings of $0.19 per share, exceeding the Zacks Consensus Estimate of a loss of $0.10 per share, but down from $1.29 per share a year ago [1][2] Financial Performance - The earnings surprise for the quarter was 290%, with a previous expectation of $0.59 per share, but the actual earnings were $0.45, resulting in a surprise of -23.73% [2] - ModivCare's revenues for the quarter ended December 2024 were $702.8 million, surpassing the Zacks Consensus Estimate by 0.51%, compared to $703.22 million in the same quarter last year [3] - The company has exceeded consensus revenue estimates two times in the last four quarters [3] Stock Performance - ModivCare shares have declined approximately 71.6% since the beginning of the year, while the S&P 500 has only decreased by 0.7% [4] - The current consensus EPS estimate for the upcoming quarter is -$0.34 on revenues of $715.67 million, and for the current fiscal year, it is $0.67 on revenues of $2.86 billion [8] Industry Outlook - The Medical Services industry, to which ModivCare belongs, is currently ranked in the top 28% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [9]

Core Viewpoint - A securities class action lawsuit has been filed against TransMedics Group, Inc. for allegedly misleading investors regarding business practices and safety issues during the Class Period from February 28, 2023, to January 10, 2025 [1][3]. Company Overview - TransMedics Group, Inc. is a medical technology company based in Andover, Massachusetts, specializing in transplant services, including the Organ Care System (OCS), which is a portable organ preservation system [2]. Allegations - The lawsuit claims that TransMedics engaged in unethical practices, including kickbacks, fraudulent overbilling, and coercive tactics to generate revenue [3]. - It is also alleged that the company concealed safety issues and lacked proper safety oversight [3]. Impact on Stock Price - Following the revelation of these allegations, TransMedics' stock price dropped significantly. On February 22, 2024, the stock fell by $2.18 (2.5%) to close at $84.81 after a letter from U.S. Rep. Paul Gosar accused the company of misappropriating resources [4]. - On January 10, 2025, after a report from Scorpion Capital, the stock fell by $3.74 (5%) to close at $68.81, and further declined by $4.76 (6.9%) to close at $64.05 on January 13, 2025 [5].

Company Overview - Auna S.A. (AUNA) is a notable stock within the Medical group, which consists of 1012 companies and is currently ranked 4 in the Zacks Sector Rank [2] - AUNA has a Zacks Rank of 2 (Buy), indicating a positive outlook based on earnings estimates and revisions [3] Performance Comparison - Year-to-date, AUNA has achieved a return of approximately 25.8%, significantly outperforming the Medical sector's average return of 6.9% [4] - In comparison, another Medical stock, BioMarin Pharmaceutical (BMRN), has returned 8.3% year-to-date, highlighting AUNA's superior performance [4] Industry Context - Auna S.A. operates within the Medical Services industry, which includes 59 stocks and is currently ranked 83 in the Zacks Industry Rank; this industry has seen an average gain of 4.1% this year [5] - BioMarin Pharmaceutical belongs to the Medical - Biomedical and Genetics industry, which has 510 stocks and is ranked 70, with a year-to-date increase of 7.1% [6]

Group 1 - Concentra Group (CON) has gained approximately 15.8% year-to-date, outperforming the average return of 6.3% for the Medical sector [4] - The Zacks Rank for Concentra Group is currently 2 (Buy), indicating a positive outlook based on earnings estimates and revisions [3] - The Zacks Consensus Estimate for CON's full-year earnings has increased by 5.4% over the past quarter, reflecting stronger analyst sentiment [3] Group 2 - Concentra Group is part of the Medical Services industry, which consists of 59 companies and currently ranks 84 in the Zacks Industry Rank [5] - The Medical Services industry has seen an average gain of 4.3% year-to-date, indicating that Concentra Group is performing better than its industry peers [5] - Another stock in the Medical sector, Cencora (COR), has also outperformed the sector with a year-to-date return of 11.6% [4]

Core Insights - Fresenius Medical Care AG & Co. (FMS) reported fourth-quarter 2024 adjusted earnings per share (EPS) of 48 cents, exceeding the Zacks Consensus Estimate by 17.1% and showing a year-over-year improvement of 2.1% [1] - The company's revenues reached $5.43 billion (EUR 5,085 million), surpassing the Zacks Consensus Estimate by 0.7%, with a year-over-year increase of 1.9% and 1.6% at constant currency [2] Revenue Details - Revenues were impacted by divestitures as part of a portfolio optimization plan, which affected revenue development by -250 basis points [2] - U.S. market revenues improved by 1.1% and 6.8% on an organic basis, driven by value-based care business and increased treatment volumes [4] - International sales declined by 10.3% reportedly and 9.7% at constant currency, but gained 3.6% organically, supported by higher reimbursement rates [6] Segmental Performance - The Care Delivery segment's revenues decreased by 0.8% year-over-year but increased by 6.3% organically [3] - The Care Enablement segment's revenues rose by 11.3% year-over-year, driven by solid volume development across regions [6] Margin Analysis - Gross profit declined by 5.9% year-over-year, with gross margin contracting by 207 basis points to 24.9% [7] - Adjusted operating income fell by 13.2% from the prior-year quarter, with the adjusted operating margin contracting by 131 basis points to 7.5% [7] Future Guidance - For 2025, Fresenius Medical expects positive revenue growth at a low-single-digit percent rate compared to the prior year, and operating income growth in the high-teens to high-twenties percent range [8] Strategic Initiatives - The FME25 transformation program delivered EUR 221 million in additional sustainable savings for 2024, exceeding the target of EUR 200 million [10] - The company plans to raise the target for sustainable annual savings to EUR 750 million by the end of 2025, with one-time costs estimated between EUR 700 million to EUR 750 million [10] - Continued divestment of noncore and dilutive assets is expected to enhance focus on core categories and improve cash resources [11]

Financial Data and Key Metrics Changes - The company reported adjusted EBITDA of $69 million for Q4 2024, significantly exceeding previous guidance [10] - Consolidated revenue growth was just over 1%, with same unit growth of 8.7%, primarily offset by the impact of portfolio restructuring [18] - Operating cash flow for Q4 was $135 million, compared to $73 million in the prior year, with a reduction in net debt from $515 million to $386 million [21][23] Business Line Data and Key Metrics Changes - The company completed a portfolio restructuring, exiting practices that represented $200 million in annual revenue, which was a drag on earnings [10] - The decline in practice-level expenses reflected the restructuring, with same unit salary expense growth remaining above the historical range of 2% to 3% [20][31] Market Data and Key Metrics Changes - The payer mix was a significant positive factor in 2024, contributing to strong operating results, although it is not expected to change significantly in 2025 [30][61] - The company anticipates flat volume in its 2025 outlook, despite some acceleration in the latter half of 2024 [37][38] Company Strategy and Development Direction - The company aims to prioritize patient-centric care, strengthen hospital relationships, and manage its improved financial position effectively [13][14] - A preliminary expectation for adjusted EBITDA in 2025 is set between $215 million and $235 million, reflecting a cautious outlook due to uncertainties in the healthcare provider space [14][17] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the company's prospects despite acknowledging headwinds in the healthcare sector [17] - The focus for 2025 includes maintaining stability in the revenue cycle management (RCM) process and seeking improvements through automation [29] Other Important Information - The company ended 2024 with cash of $230 million and plans to build cash again in 2025 [23][24] - The impact of the portfolio restructuring is expected to provide an annualized EBITDA benefit of approximately $30 million, with a third realized in 2024 [27][81] Q&A Session Summary Question: Can you provide more details on the 2025 outlook? - Management indicated that they are baking in flat volume growth and stable pricing expectations for 2025, with a focus on maintaining performance under the hybrid RCM model [36][40] Question: Are there opportunities for improved economics in NICU management? - Management confirmed ongoing discussions with hospital partners but did not incorporate any increases into their forecast [44] Question: How much of the strong pricing in Q4 came from improvements in contract admin fees? - Approximately one-third of the pricing component was attributed to hospital admin fees [75] Question: What is the expected EBITDA tailwind from exiting primary and urgent care clinics? - The exit is part of a broader restructuring, with about a third of the expected $30 million EBITDA benefit realized in 2024 and the remainder anticipated in 2025 [81] Question: What are the company's plans for capital allocation and returning cash to shareholders? - The company is focused on maintaining a strong balance sheet and will evaluate the best uses of cash, including potential debt repayment or shareholder returns [88][90]

(Exact name of registrant as specified in its charter) As filed with the U.S. Securities and Exchange Commission on March 7, 2023 Registration No. 333-259767 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 12 TO FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 JIN MEDICAL INTERNATIONAL LTD. | (State or other jurisdiction of | | --- | | incorporation or organization) | (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identificatio ...